Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and thorough QT study of single-dose sivopixant in healthy adults
jRCT2080225293Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sivopixant in cough (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and tolerability of single-dose sivopixant (Part 1) and Effect of sivopixant on QT/QTc interval (Part 2). Started Jul 2020; status: completed.
02
Drugs
sivopixant
03
Conditions
cough
Beyond the preview
Go deeper on jRCT2080225293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225293.